Cargando…
Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy
Pulmonary arterial hypertension (PAH) is defined by a heterogenous pathobiology that corresponds to variable clinical presentation, treatment response, and prognosis across affected patients. The approach to pharmacotherapeutics in PAH has evolved since the introduction of the first prostacyclin rep...
Autor principal: | Maron, Bradley A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Magdi Yacoub Heart Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590936/ https://www.ncbi.nlm.nih.gov/pubmed/33150152 http://dx.doi.org/10.21542/gcsp.2020.8 |
Ejemplares similares
-
Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
por: Leopold, Jane A., et al.
Publicado: (2016) -
Pulmonary arterial hypertension: Cellular and molecular changes in the lung
por: Maron, Bradley A.
Publicado: (2020) -
Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
por: Pullamsetti, Soni Savai, et al.
Publicado: (2023) -
Clarifying the Pulmonary Arterial Hypertension Molecular Landscape
Using Functional Genetics
por: Maron, Bradley A.
Publicado: (2020) -
New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023)